Browse investments

Invest in Mereo BioPharma Group plc on Stash

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, including BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta (OI); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency (AATD); BCT-197 (acumapimod) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); BGS-649 (leflutrozole) for the treatment of hypogonadotropic hypogonadism (HH) in obese men; OMP-305B83 (navicixizumab) for the treatment of platinum-resistant ovarian cancer, and MPH-313 (etigilimab) for patients with advanced or metastatic solid tumors.

To buy fractional shares of Mereo BioPharma Group plc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: MREO

Mereo BioPharma Group plc

$1.98

+10.61%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

MREO Performance Breakdown

Share Price

$1.98

Today's change

1.02%

Year to date change (YTD)

-42.11%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About MREO

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, including BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta (OI); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency (AATD); BCT-197 (acumapimod) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); BGS-649 (leflutrozole) for the treatment of hypogonadotropic hypogonadism (HH) in obese men; OMP-305B83 (navicixizumab) for the treatment of platinum-resistant ovarian cancer, and MPH-313 (etigilimab) for patients with advanced or metastatic solid tumors.

Mereo BioPharma Group plc Stock Ticker

MREO

For more information

https://www.mereobiopharma.com

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in Mereo BioPharma Group plc on Stash

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, including BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta (OI); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency (AATD); BCT-197 (acumapimod) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); BGS-649 (leflutrozole) for the treatment of hypogonadotropic hypogonadism (HH) in obese men; OMP-305B83 (navicixizumab) for the treatment of platinum-resistant ovarian cancer, and MPH-313 (etigilimab) for patients with advanced or metastatic solid tumors.

To buy fractional shares of Mereo BioPharma Group plc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Mereo BioPharma Group plc stock news

CNBC

Nvidia has a cash problem -- too much of it

When Nvidia this week said it would take a $2 billion stake in chip design company Synopsys, it was just the latest in a string of massive investments announced by the chipmaker this year. It's a lot of money and a lot of deals, but Nvidia's got the cash to write big checks.

about 7 hours ago

Business Insider

Uber says one stat shows how much room the company has to grow in the US

Uber's market penetration in the US is around 15%, CFO Prashanth Mahendra-Rajah said Wednesday. The statistic shows how much room Uber has to grow in its home market, Mahendra-Rajah said.

about 5 hours ago

24/7 Wall Street

2 Stocks to Play a Quantum Computing Inflection Point

A lot of smart people in tech seem to think that a potential “inflection point” in quantum computing is the real deal, and they may very well be right.

about 5 hours ago

CNBC

Bitcoin is down nearly 30% from its record high — history shows that's normal

The price of bitcoin has fallen around 36% from its all-time high recently but data shows this is a regular occurrence in the history of the cryptocurrency. In the 2021 and 2017 bitcoin cycles, there were a number of instances of drops this size or bigger.

about 8 hours ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy Mereo BioPharma Group plc stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Mereo BioPharma Group plc’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Mereo BioPharma Group plc’s price can fluctuate throughout the course of each trading day—when you buy Mereo BioPharma Group plc through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time Mereo BioPharma Group plc stock price and the Mereo BioPharma Group plc news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers two subscription plans: Stash Growth and Stash+.

Each plan can help you reach different goals and offers a unique combination of financial accounts and features. All plans include access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of Mereo BioPharma Group plc stock is complete, you'll officially be a shareholder of Mereo BioPharma Group plc!